A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis Mallory J E Loflin, Kimberly Babson, James Sottile, Sonya B Norman, Staci Gruber, and Marcel O Bonn-Miller The American Journal of Drug and Alcohol Abuse, 2019, VOL. 45, NO. 5, 506–513. Doi : 10.1080/00952990.2019.1604722 ABSTRACT Background : With a rise in public pressure to increase veteran access to medicinal cannabis, free cannabis collectives for military veterans are proliferating across the US. Objectives : The aim of the current study was to document which cannabis formulations and routes of administration are chosen by veterans with increased access to cannabis, and to determine [...]
Lire la suiteThe Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain : How Cannabis Diminished Prescription Opioid Usage Kevin M. Takakuwa, Jeffrey Y. Hergenrather, Frances S. Shofer, and Raquel M. Schears Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. Doi : 10.1089/can.2019.0039 Abstract Objective : To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design : Retrospective cohort study. Setting : A single-center cannabis medical practice site in California. Patients : A total of 180 patients who had a chief complaint of low back pain were identified (International Classification of Diseases, 10th [...]
Lire la suiteEvaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study Alex Capano, Richard Weaver & Elisa Burkman Postgraduate Medicine, 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Doi : 10.1080/00325481.2019.1685298 ABSTRACT Context : Chronic pain is highly prevalent in most of the industrialized nations around the world. Despite the documented adverse effects, opioids are widely used for pain management. Cannabinoids, and specifically Cannabidiol, is proposed as an opioid alternative, having comparable efficacy with better safety profile. Objectives : We aim to investigate the impact [...]
Lire la suiteHallucinogens and redemption Marlene Dobkin de Rios, Charles S Grob, John R Baker Journal of Psychoactive Drugs, 2002, 34, 3, 239-248. Abstract : This article examines drug substitution with regard to hallucinogens (ayahuasca, ibogaine, peyote and LSD) set within the concept of redemption. The model examines both religious and secular approaches to the contemporary use of hallucinogens in drug substitution, both by scientists and in religious setting worlwide. The redemptive model posits that the proper use of one psychoactive substance within a spiritual or clinical context helpsto free an individual from the adverse effects of their addiction to another substance and thus restores them [...]
Lire la suiteShould Physicians Recommend Replacing Opioids With Cannabis? Keith Humphreys PhD, Richard Saitz, MD, MPH JAMA, 2019, 321, 7, 639-640. doi : 10.1001/jama.2019.0077 https://jamanetwork.com/journals/jama/fullarticle/2723649 Recent state regulations (eg, in New York, Illinois) allow medical cannabis as a substitute for opioids for chronic pain and for addiction. Yet the evidence regarding safety, efficacy, and comparative effectiveness is at best equivocal for the former recommendation and strongly suggests the latter—substituting cannabis for opioid addiction treatments is potentially harmful. Neither recommendation meets the standards of rigor desirable for medical treatment decisions. Résumé : States that permit medical marijuana as an alternative to opioids for chronic pain and for addiction [...]
Lire la suite